drugset / Trial / NCT06010875
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Phase 1
Recruiting
48 enrolled
Chongqing Precision Biotech Co., Ltd
The First Affiliated Hospital of Nanchang University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.
Timeline
- Start
- 2023-11-30
- Primary completion
- 2025-12-31
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD70 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD70 CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |